Agenda
Day One (Linden Oak Room)
8:45am Welcome--Dikoe Makhene (NIAID/NIH), Sharon Nachman (SUNY Stony Brook)
Session 1: Disease Burden and Clinical Spectrum
9:00am Epidemiology/disease burden (TB, TB/HIV) -- Jeffrey Starke (Texas Children's)
9:35am Clinical spectrum --Philippa Musoke (Makerere University)
10:00am MDR and XDR TB in children--Simon Schaaf (Stellenbosch University)
10:20am TB/HIV coinfection--Mark Cotton (Stellenbosch University)
10:45-11:15am: BREAK
Session 2: Host Pathogen Interactions and Diagnostics
11:15am Immune response/correlates of protective immunity--Deborah Lewinsohn (Oregon Health and Science University)
11:50am New diagnostic technologies/methodologies--Mark Perkins (Foundation for Innovative New Diagnostics)
12:30-1:45pm: LUNCH
1:45pm Host pathogen interactions and risk factors--Ajit Lalvani (Imperial College)
2:15-4:30pm - Breakout Sessions
a) Diagnostics
b) IRIS
c) Epidemiology
4:30-5:00pm: BREAK
5:00pm Summary reports from Breakout sessions
6:00pm: ADJOURN
DAY TWO (Glenecho Room)
Session 3: Treatment
8:00am Current first and second line therapies--Peter Donald (Stellenbosch University)
8:35am SQ109--Gary Horwith (Sequella)
8:55am TMC 207--David McNeeley (Tibotec)
9:15am Moxifloxacin/PA-824--Ann Ginsberg (Global Alliance for TB Drug Development)
9:45-10:15am: BREAK
Session 4: Clinical Pharmacology and Drug-Drug Interactions
10:15am PK/PD--first and second line drugs--Charles Peloquin (National Jewish Hospital)
10:35am PK/PD—application for new drugs--George Drusano (Ordwell Research Institute)
10:55am Pharmacogenetics--Peter Donald (Stellenbosch University)
11:15am Drug-drug interactions of TB and HIV drugs--Mark Cotton (Stellenbosch University)
Session 5: Prevention
11:35am BCG vaccination--Willem Hanekom (University of Cape Town)
Noon New vaccines and vaccination strategies---Lewellys Barker (Aeras Global TB Vaccine Foundation)
12:30-1:30pm: LUNCH
1:30- 3:30pm Breakout sessions
a) Prophylaxis
b) Treatment
c) Biomarkers/Correlates for clinical efficacy
3:30-4:00pm: BREAK
4:00-5:30pm Summary reports from Breakouts
Session 6: Clinical trials and Infrastructure
5:30pm Clinical trials considerations for drugs-- William Burman (Denver Public Health )
5:50pm Trials site capacity/infrastructure-- Ann Ginsberg (Global Alliance for TB Drug Development)
6:15pm ADJOURN
Day Three (Salon D)
Session 7: Pregnancy
8:30am TB infection/tuberculosis in pregnancy--Amita Gupta (Johns Hopkins Medical Institutions)
Session 8: Regulatory Considerations
9:00am Pediatric Initiatives--William Rodriguez (Office of Pediatric Therapeutics, FDA)
9:30am Centre for Biologics--Rose Tiernan (Division of Vaccines and Related Product Applications, FDA)
9:50am Centre for Devices and Radiological Health--Freddie Poole (Office of In Vitro Diagnostic Device Evaluation and Safety, FDA)
10:10am Centre for Drug Evaluation--Eileen Navarro-Almario (Division of Special Pathogens and Immunologic Products, FDA)
10:30-11:00am BREAK
11:00am Summary reports Wednesday
11:15am Summary reports Thursday
11:30am Future Plans/Closing Remarks
Noon ADJOURN
back to top